Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Nayzilam is a prescription nasal spray containing midazolam, a benzodiazepine used to treat seizure clusters in people with epilepsy aged 12 years and older. Seizure clusters are episodes of repeated seizures that differ from a person's usual seizure pattern. Nayzilam is intended for intermittent rescue treatment rather than daily seizure prevention. It is a federally controlled Schedule IV medication.
read more about nayzilam ...Nayzilam contains midazolam, which increases the activity of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the brain. By strengthening GABA activity, midazolam reduces excessive electrical signaling associated with seizures. Its nasal delivery allows administration without swallowing a tablet during a seizure episode. Nayzilam is designed for acute treatment of recognized seizure clusters.
Nayzilam is approved for patients with epilepsy aged 12 years and older who experience intermittent seizure clusters distinct from their usual seizure activity. A healthcare professional establishes when the medication should be administered and provides a seizure action plan. Family members and caregivers should be trained in its use. Nayzilam is not approved for routine daily seizure prevention or for children younger than 12 years.
The initial Nayzilam dose is one 5 mg spray into one nostril. A second 5 mg spray may be administered into the opposite nostril after 10 minutes when prescribed and the seizure cluster has not resolved. Do not give a second dose when the patient has trouble breathing or excessive sedation. Do not exceed two doses per cluster, treat more than one episode every three days, or treat more than five episodes per month.
Common side effects include sleepiness, headache, nasal discomfort, and throat irritation. Serious risks include respiratory depression, particularly when combined with opioids, alcohol, or other central nervous system depressants. Nayzilam also carries warnings about abuse, misuse, addiction, physical dependence, and withdrawal. Caregivers should follow the prescribed seizure action plan and obtain emergency assistance for breathing problems or other specified warning signs.
No. Nayzilam is approved for intermittent seizure clusters in people with epilepsy aged 12 years and older. It is not intended to replace scheduled daily antiseizure medications.
Nayzilam is designed to act quickly after nasal administration. In clinical studies, treatment success was assessed by seizure termination within 10 minutes without recurrence during the following six hours.
A second 5 mg dose can be given after 10 minutes when prescribed and clinically appropriate. The maximum is two doses for a single seizure cluster, with restrictions on how frequently episodes are treated.
Yes. Nayzilam contains midazolam, a Schedule IV benzodiazepine. It carries risks of sedation, misuse, dependence, and potentially dangerous interactions with opioids and other sedating substances.
DailyMed - NAYZILAM (midazolam) nasal spray. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b29422e-54d5-4a49-8522-e9cf752368c3. Date Accessed October 16, 2026.
Midazolam Nasal Spray. MedlinePlus. https://medlineplus.gov/druginfo/meds/a621044.html. Date Accessed October 16, 2026.
Midazolam. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Midazolam. Date Accessed October 16, 2026.
Midazolam. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK537321/. Date Accessed October 16, 2026.
Nayzilam. UCB. https://www.ucb.com/solutions/products/nayzilam. Date Accessed October 16, 2026.